Another study [130] confirmed that the CXCR4-targeted inhibitor AMD11070 and its derivatives could induce the expression of pro-apoptotic genes from the Bcl-2 family in CXCR4-positive lymphoma cell lines while downregulating the expression levels of Jun N-terminal kinase (JNK), ERK1/2, and nuclear factor kappa-B (NF-κB); it suggested that the CXCL12-CXCR4 axis mediates the pathogenesis of diffuse large B-cell lymphoma (DLBCL), which represents a potential therapeutic target for aggressive lymphomas. The gene discussed is MAPK3; the disease is lymphoma.